通过向PARP来增强癌症免疫性
Dominik Humer1, Victoria Klepsch1, Gottfried Baier2
1Cell Genetics, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
Journal for immunotherapy of cancer
|June 24, 2025
概括
聚 ((ADP-ribose) 聚合酶 (PARP) 抑制剂诱导瘤细胞死亡,增强免疫识别和攻击. 这一发现支持PARP抑制剂作为改善癌症免疫治疗有效性的有希望的策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚 ((ADP-ribose) 聚合酶 (PARP) 抑制剂 (PARPi) 已被批准用于治疗具有同类重组修复缺陷的瘤.
- 具有DNA修复缺陷的瘤细胞可能容易受到PARPi诱导的免疫细胞死亡 (ICD).
研究的目的:
- 研究PARP抑制剂 (PARPi) 诱导免疫细胞死亡 (ICD) 和增强抗瘤免疫力的潜力.
- 通过调节瘤免疫微环境,探索PARPi在克服免疫疗法耐药性的作用.
主要方法:
- 该研究的重点是PARPi诱导瘤细胞死亡的机制及其对免疫细胞识别的影响.
- 对瘤新抗原生成和瘤免疫微环境的重编程的分析.
主要成果:
- PARPi被证明可以诱导瘤细胞死亡,从而增强免疫细胞的识别和攻击能力.
- PARPi促进瘤新抗原生成的增加,并将瘤免疫微环境重新编程为免疫刺激状态.
- PARPi可以缓解内效应T细胞免疫功能障碍,特别是在免疫疗法耐药的环境中.
结论:
- 在PARPi诱导的ICD和增强的抗瘤免疫力之间的关系表明PARPi可以使瘤对免疫治疗敏感.
- 使用PARPi与免疫检查点抑制剂或癌症疫苗的组合方法可以提高对固体瘤的疗效,并促进宿主保护性抗瘤免疫控制.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Vaccines
520
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
520
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


